ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CYP1A1	1543	9155064	Endometrioid type+ adenoacanthomas+ papillary serous carcinoma+ clear cell carcinoma+ papillar carcinoma+ mucinous carcinoma)	-	-	-	-	80 (61 endometrioid type+ 13 adenoacanthomas+ 2 papillary serous carcinoma+ clear cell carcinoma+ 1 papillar carcinoma+ 1 mucinous carcinoma)	45 to 82	-	Department of Obstetrics and Gynecology; Hospital Universitari Materno- Infantil Vall d'Hebron of Barcelona	IA (n=13); IB (n=19); IC (n=8); IIA (n=11); IIB (n=9); IIIC (n=2)	-	[1] A statistically significant association is found between endometrial carcinoma and both CYP1A1 polymorphism studied (P=0.02). The OR and CI of endometrial cancer risk for the combined genotypes of heterozygous and homozygous rare mutant alleles at the 3' end and exon 7 of the CYP1A1 gene is same: .67 (CI 1.21-13.26). [2] An association of p53 and CYP1A1 genetic polymorphism with endometrial cancer risk.	Susceptibility to endometrial cancer: influence of allelism at p53; glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci	British Journal of Cancer	75(9):1385-8	1997
CYP1A1	1543	9450474	-	Polymorphism	Molecular Marker	-	60	80	44 to 76	-	Department of Obsterics and Gynecology; Hospital Universtari MaternoInfantil Vall d'Hebron; Barcelona	I (n=35); II+III (n=45)	1 (n=40); 2+3 (n=40)	[1] There is an association between polymorphisms at the cytochrome P-450 1A1 (CYP1A1) gene and susceptibility to endometrial cancer. [2] Mutation in exon 7 of CYP1A1 gene (threonine exchanged to asparagine in codon 461) showed a strong association with endometrial cancer risk with an odds ratio of 6.36 (95% confidence interval: 1.99-26.5; P = 0.0004).	Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility	Carcinogenesis	18(12):2307-11	1997
CYP1A1	1543	18318428	Endometrioid Adenocarcinoma (137) and 13 unknown.	Polymorphism	-	-	165	150	44 to 83 yrs for patient; 43 to 83 yrs for control	60	Veterans Affairs Medical Center San Francisco.	I (n=70;47%); II (n=56; 37%); III (n=22; 15%); IV (n=2; 1%)	-	[1] A decreased frequency of TC+CC genotype of the CYP1A1 m1 (T/C) polymorphism was observed in endometrial cancer patients compared with controls (OR=0.42; 95% CI; 0.27-0.69). The T-A haplotype of CYP1A1 m1 and m2 was increased in endometrial cancer patients (p=0.017). The frequency of CYPiA1 m1 T/C +C/C was highre in CYP1A1 expression group (p=0.009). [2] The frequency of combined genotypes (SULT1A1 213 GA+AA and CYP1A1 m1 TT) was higher in endometrial cancer patients (OR; 4.58; 95% CI; 2.35-8.93). [3] The combined association of CYP1A1 and SULT gene polymorphism in endometrial cancer suggest a decreased SNP of CYP1A1 and an increased SNP for SULT1A1 and SULT1E1 genes may be risk for endometrial cancer in Caucasians.	CYP1A1; SULT1A1; and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.	Cancer	112(9):1964-73	2008